![logo](/logos/IOVA.webp)
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
10.01 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Iovance Biotherapeutics, Inc. |
Symbool | IOVA |
Munteenheid | USD |
Prijs | 10.01 |
Beurswaarde | 3,038,175,140 |
Dividendpercentage | 0% |
52-weken bereik | 3.21 - 18.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Frederick G. Vogt Esq., J.D., Ph.D. |
Website | https://www.iovance.com |
An error occurred while fetching data.
Over Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)